0
Letters |

Hypertension in Adults Across Age Groups—ReplyHypertension in Adults Across Age Groups—Reply

JAMA. 2005;294(23):2970-2972. doi:10.1001/jama.294.23.2971-b
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

HYPERTENSION IN ADULTS ACROSS AGE GROUPS—REPLY

In Reply: Drs Berlowitz and Cushman and Mr Glassman are correct in pointing out that improvements were made in blood pressure control among some subgroups during the decade of the 1990s; the VA experience that they cite is a remarkable example. Major systematic efforts were required to achieve these impressive results. Unfortunately, the success of the VA with regard to hypertension control was not mirrored in the community or in the nation as a whole during the 1990s. Data from the nationally representative NHANES samples reveal that, among all patients with hypertension, blood pressure control rates increased from approximately 25% between 1988 and 1991 to only 31% between 1999 and 2000.1 In the Framingham observational cohorts, using the same data set as in our article, we observed statistically significant increases in prevalence of blood pressure control (defined as blood pressure <140 mm Hg/<90 mm Hg) among all patients with hypertension during the 1990s, from 25% to approximately 40% (P<.001). The youngest group of patients with hypertension (those 60 years or younger) had the largest increase in control rates, to levels in excess of 50%, whereas older patients with hypertension had smaller increases, to rates in the 35% to 40% range. We await systematic improvements and greater public health and clinical efforts at blood pressure control in order to reduce the risks associated with hypertension that we reported.

Dr Cheng echoes some of the concerns we enumerated regarding treatment of hypertension in the oldest persons with hypertension, and is correct in reporting that treatment data are derived largely from individuals with stage 2 isolated systolic hypertension.2 4 In these trials, treatment was highly effective in reducing risk for stroke and heart failure, 2 critically important causes of death and permanent disability in the elderly. We agree that patients and clinicians need better data to make informed decisions. Treatment trials of stage 1 isolated systolic hypertension in the oldest patients with hypertension would help determine whether and to what extent treatment is beneficial; in the absence of such information, we must rely on indirect evidence from observational studies in conjunction with relevant information from existing clinical trials. For example, a meta-analysis of 1670 patients 80 years and older who were enrolled in clinical trials revealed significant and substantial reductions in stroke and heart failure events associated with antihypertensive therapy, with a small and statistically nonsignificant increase in total mortality.5 The results of the Hypertension in the Very Elderly Trial (HYVET)6 are eagerly awaited, and more studies should be undertaken.

Financial Disclosures: None reported.

References
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.  JAMA. 2003;290199-206
PubMed
SHEP Cooperative Research Group.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program.  JAMA. 1991;2653255-3264
PubMed
Staessen JA, Fagard R, Thijs L.  et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Lancet. 1997;350757-764
PubMed
Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative Group.  J Hypertens. 1998;161823-1829
PubMed
Gueyffier F, Bulpitt C, Boissel J-P.  et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials.  Lancet. 1999;353793-796
PubMed
Bulpitt C, Fletcher AE, Beckett N.  et al.  Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.  Drugs Aging. 2001;18151-164
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.  JAMA. 2003;290199-206
PubMed
SHEP Cooperative Research Group.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program.  JAMA. 1991;2653255-3264
PubMed
Staessen JA, Fagard R, Thijs L.  et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Lancet. 1997;350757-764
PubMed
Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative Group.  J Hypertens. 1998;161823-1829
PubMed
Gueyffier F, Bulpitt C, Boissel J-P.  et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials.  Lancet. 1999;353793-796
PubMed
Bulpitt C, Fletcher AE, Beckett N.  et al.  Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.  Drugs Aging. 2001;18151-164
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.